

Treatment of Intermittent Claudication due to Peripheral Arterial Disease

Wilbert S Aronow*

Cardiology Division, New York Medical College, Macy Pavilion, Room 138, Valhalla, NY 10595, USA

*Corresponding author: Wilbert S Aronow, Cardiology Division, New York Medical College, Macy Pavilion, Room 138, Valhalla, NY 10595, USA, Tel: (914) 493-5311; Fax: (914) 235-6274; E-mail: wsaronow@aol.com

Rec date: March 23, 2015; Acc date: March 24, 2015; Pub date: March 31, 2015

Copyright: © 2015 Aronow WS. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Editorial

Peripheral arterial disease may cause intermittent claudication which is pain or weakness with walking that is relieved with rest [1]. Patients with intermittent claudication should be treated with optimal medical therapy to reduce cardiovascular death, nonfatal myocardial infarction, and stroke and also to improve exercise time until intermittent claudication [1]. Optimal medical therapy to reduce cardiovascular events and mortality in patients with peripheral arterial disease include smoking cessation programs [1], treatment of hypertension [1-3], treatment of hypercholesterolemia [1,4], treatment of diabetes mellitus [1,5], antiplatelet drug therapy [1,6-8], treatment with an angiotensin-converting enzyme inhibitor [1,3], treatment with high-dose statins [1,4,9], and treatment with beta blockers if indicated in patients with mild-to moderate peripheral arterial disease [1,10]. Vorapaxar [11] has recently been approved by the United States Food and Drug Administration to treat patients with peripheral arterial disease receiving aspirin or clopidogrel to reduce the need for peripheral artery revascularization. This drug should not be used in patients with a history of stroke or transient ischemic attack or bleeding in the head.

The American College of Cardiology Foundation/American Heart Association guidelines recommend that cilostazol 100 mg orally 2 times daily is indicated to improve symptoms and increase walking distance in patients with intermittent claudication due to lower extremity peripheral arterial disease in the absence of heart failure [1]. In addition to reducing cardiovascular events and mortality, statins also have been demonstrated in randomized, placebo-controlled studies to improve exercise time until intermittent claudication [12-14]. A randomized, placebo-controlled trial showed that in 212 patients with intermittent claudication due to peripheral arterial disease, 24-week treatment with ramipril caused a significant 75 second increase in mean pain-free walking time, a significant 255 second increase in maximum walking time, and a significant improvement in the overall SF-36 median Physical Component Summary score by 8.2 [15].

Exercise rehabilitation programs have been found to increase walking distance in patients with intermittent claudication through improvements in peripheral circulation, walking economy, and cardiopulmonary function [16]. The optimal exercise program for improving claudication pain distance in patients with peripheral arterial disease uses intermittent walking to near-maximal pain during a program of at least 6 months [17]. Strength training is not as effective as a treadmill walking program [18]. A home-based walking exercise program significantly improved walking endurance, physical activity, and speed in patients with peripheral arterial disease and should be used by patients unwilling to participate in a supervised exercise training program [19]. The American College of Cardiology Foundation/American Heart Association guidelines recommend a

supervised exercise program for patients with intermittent claudication [1]. Supervised exercise training should be performed for a minimum of 30-45 minutes in sessions performed at least 3 times per week for a minimum of 12 weeks [1], and preferably for 6 months or longer [17].

Endovascular procedures and surgical interventions for intermittent claudication are indicated for patients with intermittent claudication who have a vocational or lifestyle-limiting disability when clinical features suggest a reasonable likelihood of symptomatic improvement with the intervention and there has been an inadequate response to exercise and pharmacological treatment or there is a very favorable risk-benefit ratio as in focal aortoiliac occlusive arterial disease [1]. Patients with intermittent claudication should be considered for revascularization to improve symptoms only in the absence of other disease that would limit exercise improvement such as angina pectoris, heart failure, chronic pulmonary disease, or orthopedic limitations [1]. Endovascular or surgical intervention is not indicated as prophylactic therapy in an asymptomatic patient with lower extremity peripheral arterial disease or to prevent progression to limb-threatening ischemia in patients with intermittent claudication [1].

The Claudication Exercise Versus Endoluminal Revascularization (CLEVER) study randomized 111 patients with intermittent claudication due to aortoiliac peripheral arterial disease to optimal medical therapy, optimal medical therapy plus supervised exercise, or optimal medical therapy plus stent revascularization [20]. This study showed at 6-month follow-up that the greatest increase in treadmill walking performance occurred in the patients randomized to optimal medical therapy plus supervised exercise [20]. Seventy-nine of the 111 patients (71%) in the CLEVER study completed the 18-month clinical and treadmill follow-up assessment [21]. Supervised exercise consisted of 6 months of supervised exercise and an additional year of exercise counseling by telephone. Peak walking time increased from baseline to 18 months 5.0 minutes more with supervised exercise than with optimal medical therapy (0.2 minutes) ($p<0.001$) [21]. Peak walking time increased from baseline to 18 months 3.2 minutes more with supervised exercise than with optimal medical therapy (0.2 minutes) ($p=0.04$) [21]. These data support a supervised exercise program as a durable primary treatment of intermittent claudication due to peripheral arterial disease [21].

References

1. Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, et al. (2013) Management of patients with peripheral artery disease (compilation of 2005 and 2011 ACCF/AHA guideline recommendations). A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation* 127: 1425-1443.
2. Aronow WS, Fleg JL, Pepine CJ, Artinian NT, Bakris G, et al. (2011) ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly. A Report of the American College of Cardiology Foundation Task

- Force on Clinical Expert Consensus Documents. Developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society for Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. *J Am Coll Cardiol* 57: 2037-2114.
3. Ostergren J, Sleight P, Dagenais G, Danisa K, Bosch J, et al. (2004) Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. *Eur Heart J* 25: 17-24.
4. Stone NJ, Robinson J, Lichtenstein AH, Merz CNB, Blum CB, et al. (2014) 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol* 63: 2889-2934.
5. Aronow WS, Ahn C, Weiss MB, Babu S (2007) Relation of increased hemoglobin A(1c) levels to severity of peripheral arterial disease in patients with diabetes mellitus. *Am J Cardiol* 99: 1468-1469.
6. Antithrombotic Trialists' Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. *BMJ* 324: 71-86.
7. CAPRIE Steering Committee (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. *Lancet* 348: 1329-1339.
8. Wong PF, Chong LY, Stansby G (2013) Antiplatelet therapy to prevent cardiovascular events and mortality in patients with intermittent claudication. *JAMA* 309: 926-927.
9. Aronow WS, Ahn C (2002) Frequency of new coronary events in older persons with peripheral arterial disease and serum low-density lipoprotein cholesterol ≥ 125 mg/dl treated with statins versus no lipid-lowering drug. *Am J Cardiol* 90:789-791.
10. Aronow WS, Ahn C (2001) Effect of beta blockers on incidence of new coronary events in older persons with prior myocardial infarction and symptomatic peripheral arterial disease. *Am J Cardiol* 87: 1284-1286.
11. Bonaca MP, Scirica BM, Creager MA, Olin J, Bounameaux H, et al. (2013) Vorapaxar in patients with peripheral artery disease: results from TRA2{degrees}P-TIMI 50. *Circulation* 127: 1522-1529, 1529e1-6.
12. Aronow WS, Nayak D, Woodworth S, Ahn C (2003) Effect of simvastatin versus placebo on treadmill exercise time until the onset of intermittent claudication in older patients with peripheral arterial disease at 6 months and at 1 year after treatment. *Am J Cardiol* 92: 711-712.
13. Mohler ER III, Hiatt WR, Creager MA, for the Study Investigators (2003) Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. *Circulation* 108: 1481-1486.
14. Mondillo S, Ballo P, Barbati R, Guerrini F, Ammataro T, et al. (2003) Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease. *Am J Med* 114: 359-364.
15. Ahimastos AA, Walker PJ, Askew C, Leicht A, Pappas E, et al. (2013) Effect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: a randomized controlled trial. *JAMA* 309: 453-460.
16. Hamburg NM, Balady GJ (2011) Exercise rehabilitation in peripheral artery disease: functional impact and mechanisms of benefits. *Circulation* 123: 87-97.
17. Gardner AW, Poehlman ET (1995) Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis. *JAMA* 274: 975-980.
18. Hiatt WR, Wolfel EE, Meier RH, Regensteiner JG (1994) Superiority of treadmill walking exercise versus strength training for patients with peripheral arterial disease. Implications for the mechanism of the training response. *Circulation* 90: 1866-1874.
19. McDermott MM, Liu K, Guralnik JM, Criqui MH, Spring B, et al. (2013) Home-based walking exercise intervention in peripheral artery disease: a randomized clinical trial. *JAMA* 310: 57-65.
20. Murphy TP, Cutlip DE, Regensteiner JG, Mohler ER, Cohen DJ, et al. (2012) Supervised exercise versus primary stenting for claudication resulting from aortoiliac peripheral artery disease. Six-month outcomes from the Claudication: Exercise Versus Endoluminal Revascularization (CLEVER) Study. *Circulation* 125: 130-139.
21. Murphy TP, Cutlip DE, Regensteiner JG, Mohler ER, Cohen DJ, et al. (2015) Supervised Exercise, Stent Revascularization, or Medical Therapy for Claudication Due to Aortoiliac Peripheral Artery Disease: The CLEVER Study. *J Am Coll Cardiol* 65: 999-1009.